GARRY GRAYSON: Open Payments
NPI 1043260409 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$203 in 8 payments from 7 companies in 2025. Trend: 2023 $148 · 2024 $156 · 2025 $203
Food & beverage: $203
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $56 |
| Neurocrine BioSciences, Inc. | 1 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
Products named: REXULTI, INGREZZA, FANAPT, TRINTELLIX, CAPLYTA, UZEDY.
Industry payments across AL — which companies pay providers there.
